Highly substituted hydroxyethyl starch (HES200/0.62) leads to Type-I von Willebrand syndrome after repeated administration

Haemostasis. 1996 Jul-Aug;26(4):210-3. doi: 10.1159/000217209.

Abstract

Hydroxyethyl starch (HES) is a frequently used plasma substitute that is popular due to a high degree of therapeutic safety. However, the administration of large volumes of highly substituted, high-molecular-weight starch often leads to iatrogenic von Willebrand syndrome (vWS) with hemorrhagic complications. In patients with cerebral circulatory disturbances we carried out hemodilution therapy during 9-10 days, infusing HES 200/0.62. A von Willebrand factor (vWF) multimeric analysis was carried out in 6 patients using a modified western blot according to the sodium dodecyl sulfate agarose gel electrophoresis method. The vWF multimeric analysis showed that all multimers decreased to the same degree, corresponding to type-I vWS.

MeSH terms

  • Aged
  • Cerebrovascular Disorders / drug therapy*
  • Female
  • Gingival Hemorrhage / chemically induced
  • Hemodilution
  • Humans
  • Hydroxyethyl Starch Derivatives / administration & dosage
  • Hydroxyethyl Starch Derivatives / adverse effects*
  • Hydroxyethyl Starch Derivatives / therapeutic use
  • Ischemic Attack, Transient / drug therapy*
  • Male
  • Middle Aged
  • Molecular Weight
  • Partial Thromboplastin Time
  • Plasma Substitutes / administration & dosage
  • Plasma Substitutes / adverse effects*
  • Plasma Substitutes / therapeutic use
  • von Willebrand Diseases / chemically induced*
  • von Willebrand Factor / antagonists & inhibitors*
  • von Willebrand Factor / chemistry

Substances

  • Hydroxyethyl Starch Derivatives
  • Plasma Substitutes
  • von Willebrand Factor